Comparative pharmacokinetic analysis of a novel sustained release dosage form of valproic acid in dogs
- 1 January 1984
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 5 (1) , 1-10
- https://doi.org/10.1002/bdd.2510050102
Abstract
A new sustained release dosage form of valproic acid (VPA) was developed. The new sustained release dosage form was administered (twice, with and without food) to five dogs in comparison to a standard tablet (Depakine, Labaz) and an i.v. preparation of the drug. Drug level monitoring in the plasma was performed by a GLC assay. Results indicate that the sustained release formulation exhibited a more prolonged and uniform absorption rate, yielded more sustained plasma levels after ingestion, and showed an overall bioavailability of 0·84 (95 per cent C.I. = 0·72, 0·96) relative to an equivalent dose of a conventional tablet.Keywords
This publication has 9 references indexed in Scilit:
- Once‐daily Sodium Valproate in the Treatment of EpilepsyDevelopmental Medicine and Child Neurology, 1980
- Clinical Pharmacokinetics of Valproic Acid1Clinical Pharmacokinetics, 1980
- Monitoring of Free Valproic Acid Levels?Therapeutic Drug Monitoring, 1980
- Sodium valproateNeurology, 1979
- Valproic AcidArchives of Neurology, 1979
- Clinical Pharmacological Aspects of Valproate SodiumEpilepsia, 1977
- Concentration of Dipropylacetate in PlasmaEpilepsia, 1975
- The effect of food on the in vivo release of propranolol from a PVC matrix tablet in the dogJournal of Pharmacy and Pharmacology, 1974
- New Method for Calculating the Intrinsic Absorption Rate of DrugsJournal of Pharmaceutical Sciences, 1968